ClinicalTrials.gg
RecruitingNCT04998773EMTtfNIUpdated Feb 22, 2024

Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression

An interventional study of Theta Burst Transcranial Magnetic Bilateral Stimulation and Theta Burst Transcranial Magnetic Sham Stimulation in Resistant Depression, Treatment and Bipolar Depression, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain — 4 open to participants now, 5 under way, 2 of them phase 3. Depressive Disorder, Treatment-Resistant · Spain.

Planned enrollment
12th of 17
96 · median 196
Started
2021
the only one that year
No phase
4 of 18
3 open now
Registered
11th of 18
by date
Lead sponsor
1 of 18
Instituto de Investigacion Sanitaria La Fe

Among the 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2021, is one of 4 with no phase, and was the 11th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain, or all of them as a file.
02

Study summary

Theta Burst Transcranial Magnetic Stimulation (TBS) in dorsolateral prefrontal cortex (DLPFC) has shown efficacy and safety as an adjuvant strategy for resistant to treatment depression (RTD) in daily sessions during 4-6 weeks (20-30 sessions). Current investigation in TBS aims to design intensive treatment protocols so as to achieve earlier responses and higher rates of efficacy. However, the implementation of TBS in the Public National Health Service requires cost-effective protocols that ensure and facilitate patients adherence to treatment, and whose design is based on clinical and neuroimaging biomarkers of response so as to adequately select candidate patients. The aim of this study is to assess the efficacy and safety of novel bilateral and unilateral intensive and spaced protocols of TBS in outpatients with unipolar and bipolar RTD compared with sham stimulation. Specific objectives: I) Comparison of mood change, response and remission of depressive illness at the end of TBS protocol in the groups and maintenance of its effect at 3 months; II) Characterization of neuroimaging cerebral connectivity networks and cerebral metabolism patterns of patients with RTD related to the effects of bilateral or unilateral TBS; III) Identification of clinical and demographic predictors contributing to response to TBS; IV) Analysis of the interaction between clinical, demographic and neuroimaging predictors so as to determine a RTD profile of patient that can benefit from TBS.

Read the detailed description

Participants will receive 22 bilateral sessions of sham/active continuous (right DLPFC) and intermittent (left DLPFC) TBS during 6 weeks. Simultaneous cerebral PET-MRI will be performed before (week 0) and after the treatment with TBS (week 7)

  • Weeks 1 and 2: 1 session 5 days a week (10 sessions)
  • Weeks 3,4,5, 6: 1 session 3 days a week (12 sessions)
03

Conditions studied

  • Resistant Depression, Treatment
  • Bipolar Depression

Keywords

  • TMS
  • iTBS
  • Depression
  • Bipolar depression
  • Antidepressants
  • Neuroimaging
  • PET-MRI
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Major Depressive Episode or Depressive phase in Bipolar Disorder criteria.
  • Moderate severity (>14 points in HDRS)
  • 2 antidepressant failures or failure in enhancing strategies in the case of bipolar depression.
  • No changes in treatment 3 week previous to the onset of treatment with TMS.
  • Ability to sign .

Exclusion criteria

Exclusion Criteria:

  • Any psychiatric comorbidity in axis I or II.
  • Depressive episode with psychotic features.
  • Dysthymia.
  • Treatment with ECT in current depressive episode.
  • Multiresistance (> 6 trials of therapeutic strategies).
  • Suicide risk assessed previous to each session.
  • Patients who miss 2 TMS sessions in a row
  • Neurological comorbidities (epilepsy, Parkinson disease, neurocognitive disorders).
  • to TMS: pregnancy, metallic cervical or head implants.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    Group Bilateral

    32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC

    Device: Theta Burst Transcranial Magnetic Bilateral Stimulation

  • Active comparator
    Group Unilateral

    32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC

    Device: Theta Burst Transcranial Magnetic Unilateral Stimulation

  • Placebo comparator
    Group Placebo

    32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC

    Device: Theta Burst Transcranial Magnetic Sham Stimulation

Interventions

  • DeviceTheta Burst Transcranial Magnetic Bilateral Stimulation

    TMS protocol of 22 sessions of bilateral active 1800 pulses.

  • DeviceTheta Burst Transcranial Magnetic Sham Stimulation

    TMS protocol of 22 sessions of sham bilateral 1800 pulses.

  • DeviceTheta Burst Transcranial Magnetic Unilateral Stimulation

    TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale 17 items (HDRS-17) at the end of the treatment respect to basal.

    Hetero-administered

    Time frame: 6 weeks

Secondary outcomes

  1. Beck Depression Inventory (BDI-II) respect to basal.

    Self-administered

    Time frame: 2, 6 weeks

  2. Montgomery Asberg Depression Rating Scale (MADRS) respect to basal.

    Hetero-administered

    Time frame: 2, 6 weeks

  3. Young Mania Rating Scale (YMRS) at the end of the treatment respect to basal.

    Hetero-administered

    Time frame: 2, 6 weeks

  4. Altman Self Rating Mania Scale (ASRM) at the end of the treatment respect to basal.

    Self-administered

    Time frame: 2, 6 weeks

  5. Clinical Global Impression Scale (CGI) respect to basal.

    Hetero-administered

    Time frame: 2,6 weeks

  6. Hamilton Anxiety Scale (HAM-A) respect to basal.

    Hetero-administered

    Time frame: 2,6 weeks

  7. Oviedo Sleep Questionnaire (OSQ) respect to basal.

    Hetero-administered

    Time frame: 2, 6 weeks

  8. Dimensional Apathy Scale (DAS) respect to basal

    Self-administered

    Time frame: 6 weeks

  9. Screening for Cognitive Impairment por Psychiatry (SCIP) at the end of the treatment respect to basal.

    Hetero-administered (versions A and B)

    Time frame: 6 weeks

  10. Short Form Health Survey (SF 36) at the end of the treatment respect to basal.

    Self-administered

    Time frame: 6 weeks

  11. Functional Assessment Short Test (FAST) at the end of the treatment respect to basal.

    Hetero-administered

    Time frame: 6 weeks

  12. Global assessment of Functioning (GAF) at the end of the treatment respect to basal.

    Hetero-administered

    Time frame: 6 weeks

  13. Response to treatment

    50% reduction in HDRS-17

    Time frame: 2 and 6 weeks

  14. Response to treatment

    50% reduction in MADRS

    Time frame: 2 and 6 weeks

  15. Remission

    HDRS-17\<8 points

    Time frame: 2 and 6 weeks

  16. Remission

    MADRS\<11 POINTS

    Time frame: 2 and 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum In: Lancet. 2018 Jun 23;391(10139):e24. doi: 10.1016/S0140-6736(18)31323-0. PubMed 29726344 ↗
  • Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul. 2020 Jan-Feb;13(1):137-144. doi: 10.1016/j.brs.2019.08.013. Epub 2019 Aug 22. PubMed 31477542 ↗
  • Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, Tu PC, Bai YM, Tsai SJ, Lee YC, Su TP. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014 Jul;137(Pt 7):2088-98. doi: 10.1093/brain/awu109. Epub 2014 May 10. PubMed 24817188 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Feb 2025, 41 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 41 months is close to that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 10, 2021
StartActual
Sep 15, 2021
Primary completionEst.
Feb 2025
CompletionEst.
Feb 28, 2025
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04998773
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Collaborators
Spanish Agency of Medicines and Health Products, Hospital Universitario La Fe, Instituto de Salud Carlos III
Responsible party
Pilar Sierra Sanmiguel (Principal Investigator, Leader of Mental Health Investigation Group, Instituto de Investigacion Sanitaria La Fe) — Principal investigator
First posted
Aug 10, 2021
Start date
Sep 15, 2021
Primary completion
Feb 2025 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Feb 22, 2024

Study contacts

Yolanda Cañada, MD
Contact
canyada_yol@gva.es
+34961244154
Pilar Sierra San Miguel, PhD
principal investigator · Instituto de Investigación Sanitaria La Fe

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion